Comparison of Jacobson Relaxation Technique and Pranayama Technique in Patients With COPD

June 12, 2024 updated by: Riphah International University
Comparison of Jacobson Relaxation Technique and Pranayama Technique in patients with COPD

Study Overview

Detailed Description

Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that cause obstructed airflow from the lungs. Symptoms include Breathing difficulty. cough, mucus production and wheezing. Its typically caused by long term exposure to irritating gasses or particulate matter, most often from cigarette smoker. in this study we compare the effect of Jacobson relaxation technique and Pranayama technique on the SOB, Cough, sputum and quality of life in COPD patients.

Data were collected from Gulab Devi Chest Hospital, General Hospital, Jinnah Hospital and Mayo Hospital Lahore. Data were collected by the lottery method. Borg dyspnea scale, Spirometry, CASA-Q and Quality of life questionnaire were used before and after the intervention. Treatment was continuous 4 weeks, 3 times in a week for 15 mint. Assessment was done through the tool before and after the treatment.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • Gulab Devi Chest Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • • Patients of Age between 40 and 70.

    • Both Genders (Male, Female) were included.
    • Stage 2 patient with COPD with Dyspnea FEV1 <70% and Maximal Expiratory Pressure = 50% (Gold Criteria) were included.
    • Cognitive Stable patients were included.
    • Those Patients were included who were clinically stable without exacerbations in the past 01 month.

Exclusion Criteria:

  • • Common Cough

    • Upper respiratory tract inflammation
    • Patients who have other co-morbid diseases which prevents them from exercise training, for example, disability due to neurological, orthopedic and acute cardiac causes
    • Patients who were mentally and physically and sick to join at the hospital or research site for training
    • Patients who were already participated or completed or in a P.R program in the past one year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Jacobson's Technique

Participant in the group A were instructed to perform the Jacobson relaxation technique.

  • Quite place were chosen where there is no disturbance.
  • Patients were relax either on the lying position or sitting position with head well-supported.
  • Patients were instructed to loosen any tight clothing.
  • Patients were educated for muscles of each group emphasis on attention on that muscle group only.
  • Repeat this three times, constrict the muscle and then relax, tens the muscle and maintain it for five seconds then relax it lightly and then tense and relax. Constrict the muscle very slightly then relax it. Focus on each muscle group and then decide to relax the target muscle.
Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
Active Comparator: Pranayama Technique

Participant in group B were instructed to perform the pranayama relaxation technique.

  • Quite place were chosen where there is no disturbance and patient were relaxed in sitting position with spine straight.
  • In this technique patients were instructed to perform different type of pranayama techniques.
  • Guide the participants to take a steady breath in through your both nostrils. Then inhale until you reach your total lung capacity, maintaining a tall spine.

Treatment was continuous 4 weeks, 3 times in a week for 15 mint. Assessment was done through the tool before and after the treatment.

Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dyspnea Severity (Borg Scale)
Time Frame: 4 weeks

The Borg scale measures the severity of dyspnea (shortness of breath).

Scale Details:

Full Title: Borg Rating of Perceived Exertion (RPE) ScaleFull Title: Borg Rating of Perceived Exertion (RPE) Scale Minimum Value: 0 (No breathlessness at all) Maximum Value: 10 (Maximal breathlessness) Interpretation: Higher scores indicate worse outcomes, meaning greater severity of dyspnea.

4 weeks
Cough and Sputum Analysis (CASA-Q)
Time Frame: 4 Weeks

The CASA-Q (Cough and Sputum Assessment Questionnaire) evaluates the severity and impact of cough and sputum production.

Scale Details:

Full Title: Cough and Sputum Assessment Questionnaire (CASA-Q) Minimum Value: 0 (No symptoms) Maximum Value: 100 (Severe symptoms) Interpretation: Higher scores indicate worse outcomes, meaning more severe symptoms of cough and sputum.

4 Weeks
Spirometry (FEV1 and FVC)
Time Frame: 4 Weeks

Spirometry will be used to measure lung function, specifically Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC).

Scale Details:

Full Title: Spirometry (FEV1 and FVC) Minimum Value: Variable (dependent on patient's lung function) Maximum Value: Variable (dependent on patient's lung function) Interpretation: Higher values typically indicate better lung function.

4 Weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life (SF-36 Questionnaire)
Time Frame: 4 Weeks

The SF-36 (Short Form Health Survey) questionnaire assesses the overall quality of life.

Scale Details:

Full Title: SF-36 Health Survey Minimum Value: 0 (Worst possible health state) Maximum Value: 100 (Best possible health state) Interpretation: Higher scores indicate better quality of life.

4 Weeks
Patient Satisfaction (Patient Satisfaction Questionnaire)
Time Frame: 4 Weeks

The Patient Satisfaction Questionnaire measures the satisfaction of patients with the treatment they received.

Full Title: Patient Satisfaction Questionnaire (PSQ) Minimum Value: 1 (Very dissatisfied) Maximum Value: 5 (Very satisfied) Interpretation: Higher scores indicate greater satisfaction.

4 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sumera Hameed, MS, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 20, 2023

Primary Completion (Actual)

December 1, 2023

Study Completion (Actual)

December 10, 2023

Study Registration Dates

First Submitted

March 4, 2024

First Submitted That Met QC Criteria

June 12, 2024

First Posted (Actual)

June 17, 2024

Study Record Updates

Last Update Posted (Actual)

June 17, 2024

Last Update Submitted That Met QC Criteria

June 12, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • REC/ 31831 Iqra

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Jacobsons Breathing Technique

Subscribe